Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab and iscalimab versus placebo in systemic lupus erythematosus
2018-001508-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ianalumab and iscalimab in systemic lupus erythematosus (SLE) (4 arms), sponsored by Novartis. Primary endpoint: SRI-4 response with maintained reduced steroid dose at Week 29. Started Aug 2018; status: completed.
02
Drugs
ianalumabiscalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-001508-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001508-12.